文献速递类风湿关节炎

SB5阿达木单抗生物类似药与参照阿达木单抗在中重度类风湿关节炎中的III期随机研究

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2017-11-21

这项III期随机双盲平行组研究评估了SB5(阿达木单抗生物类似药)与参照阿达木单抗在甲氨蝶呤治疗下仍中重度活动的类风湿关节炎患者中的疗效、药代动力学、安全性和免疫原性。主要终点为第24周ACR20应答率,符合方案集分析显示SB5组与参照阿达木单抗组分别为72.4%和72.2%,差异0.1%(95%CI -7.83%, 8.13%),在预设等效界值±15%内,其他终点包括ACR50/70、DAS28-ESR、药代动力学、不良事件和抗药抗体应答均具有可比性。

要点

  • 第24周ACR20应答率SB5组72.4%与参照阿达木单抗组72.2%等效,差异0.1%(95%CI -7.83%, 8.13%)。
  • 其他疗效终点、药代动力学、安全性和抗药抗体应答在两组间具有可比性。
  • 亚组分析显示无论抗药抗体状态如何,SB5与参照阿达木单抗的疗效和安全性相当。

核心结论

  • 在中重度活动性类风湿关节炎患者中,SB5与参照阿达木单抗第24周ACR20应答率等效,且安全性和免疫原性具有可比性。

研究设计与样本

  • III期随机双盲平行组研究,随机1:1接受SB5或参照阿达木单抗40 mg皮下注射每两周一次。
  • 共544例患者随机,全分析集542例(SB5组269例,参照阿达木单抗组273例),符合方案集476例(SB5组239例,参照阿达木单抗组237例)。
  • 主要疗效终点为符合方案集(完成者分析)第24周基于ACR20的应答率。

主要发现

  • 符合方案集第24周ACR20应答率SB5组为72.4%,参照阿达木单抗组为72.2%,差异0.1%(95%CI -7.83%, 8.13%),在预设等效界值±15%内。
  • 全分析集(缺失数据视为无应答)结果相似。
  • ACR50和ACR70应答率、基于红细胞沉降率的DAS28、药代动力学数据、治疗中出现的不良事件发生率和抗药抗体应答在两组间具有可比性。
  • 亚组分析显示无论抗药抗体状态如何,SB5与参照阿达木单抗的疗效和安全性相当。

关键数值与推荐

  • 主要终点等效性界值为±15%,第24周ACR20应答率差异0.1%(95%CI -7.83%, 8.13%)落在界值内。

临床怎么用

  • SB5可作为参照阿达木单抗的生物类似药用于中重度活动性类风湿关节炎患者,疗效、安全性和免疫原性具有可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: SB5 is a biosimilar agent for adalimumab (ADA). The aim of this study was to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of SB5 in comparison with reference ADA in patients with rheumatoid arthritis (RA). METHODS: In this phase III, randomized, double-blind, parallel-group study, patients with moderately to severely active RA despite treatment with methotrexate were randomized 1:1 to receive SB5 or reference ADA at a dosage of 40 mg subcutaneously every other week. The primary efficacy end point was the response rate based on the American College of Rheumatology 20% improvement criteria (ACR20) at week 24 in the per-protocol set (completer analysis). Additional end points included efficacy, PK, safety, and immunogenicity assessments. RESULTS: Of the 544 patients randomized to receive a study drug, the full analysis set comprised 542 patients (269 in the SB5 group, 273 in the reference ADA group) and the per-protocol set comprised 476 patients (239 receiving SB5, 237 receiving reference ADA). The ACR20 response rate at week 24 in the per-protocol set was equivalent between those receiving SB5 and those receiving reference ADA (72.4% and 72.2%, respectively); the difference in the ACR20 response rate (0.1%, [95% confidence interval -7.83%, 8.13%]) was within the predefined equivalence margin (±15%). Similar results were seen in the full analysis set (missing data being considered a nonresponse). The SB5 and reference ADA treatment groups were comparable across other end points, including the ACR 50% and ACR 70% improvement response rates, Disease Activity Score in 28 joints based on the erythrocyte sedimentation rate, PK data, incidence of treatment-emergent adverse events, and the antidrug antibody response. Subgroup analyses showed that the efficacy and safety of SB5 and reference ADA were comparable regardless of antidrug antibody status. CONCLUSION: The ACR20 response rate at week 24 was equivalent between patients treated with the biosimilar agent SB5 and those treated with reference ADA. SB5 and reference ADA were both well tolerated, with comparable safety profiles, in patients with RA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. Arthritis Rheumatol. 2017. PMID: 28950421. doi:10.1002/art.40336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。